References
- Diczfalusy E. Gregory Pincus and steroidal contraception. Acta Obstet Scand Suppl 1982;105:7–15.
- Davis KS. The story of the pill. American Heritage Magazine 1978;29:1–9. htp://www.americanheritage.com/articles/magazine/ah/1978/5/1978_5_80.shtml
- Speroff L. A good man – Gregory Goodwin Pincus. Portland, Oregon: Arnica Publishing, Inc, 2009.
- Gladwell M. John Rock's error. The New Yorker,13 March 2000; 52–63.
- White Junod S, Marks L. Women's trials: The approval of the first oral contraceptive pill in the United States and Great Britain. J Hist Med 2002;57: 117–60.
- Netter A, Rozenbaum H. La contraception orale. In Histoire illustrée de la contraception de l'Antiquité à nos jours. Paris: Editions Roger Dacosta 1985; 339–71.
- Benagiano G, Bastianelli C, Farris M. Contraception today. Ann NY Acad Sci 2006;1092:1–32.
- Kiley J, Hammond C. Combined oral contraceptives: A comprehensive review. Clin Obstet Gynecol 2007;50:868–77.
- Risk of thromboembolic disease in women taking oral contraceptives. A preliminary communication to the Medical Research Council by a Subcommittee. Br Med J 1967;2:355–9.
- Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception 2006;74:439–45.
- Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence 2009;3:131–43.
- WHO. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575–82.
- Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593–6.
- Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589–93.
- van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. doi: 10.1136/bmj.b2921.
- Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. doi: 10.1136/bmj.b2890.
- Reid RL, Westhoff C, Mansour D, et al. Oral contraceptives and venous thromboembolism. Consensus opinion from an international workshop held in Berlin, Germany in December 2009. J Fam Plann Reprod Health Care 2010;36:117–22.
- Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169–78.
- Wiegratz I, Kuhl H. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care 2006;11:153–61.
- Calaf i Alsina J. After 50 years of ethinylestradiol, another oestrogen in combined oral contraceptives. Eur J Contracept Reprod Health Care 2010;15:1–3.
- Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927. doi: 10.1136/bmj.c927.
- Trussell J. Contraceptive efficacy. Contraceptive technology, In Hatcher RA, Trussell J, Nelson AL, et al., eds. 19th revised ednNew York, NYArdent Media2007. http://www.contraceptivetechnology.org/